GMAB:NSD-Genmab A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 44.40

Change

0.00 (0.00)%

Market Cap

USD 28.77B

Volume

1.28M

Average Target Price

USD 40.00 (-9.91%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Company Website : http://www.genmab.com

Address : Kalvebod Brygge 43, Copenhagen, Denmark, 1560

Employees : 712

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.59

52 Week High : 44.83

Short Ratio : 2.15

52 Week Low : 16.24

Shorted Shares : 867,726

200 Day Moving Average : 37.15

Shorted Shares Previous Month : 594,652

50 Day Moving Average : 40.06

Shares Held by Institutions : 6.32%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD55.27B 18.98 14.64
MRNA Moderna, Inc

N/A

 USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD34.27B 36.37 33.83
SGEN Seagen Inc

N/A

 USD33.25B 70.15 70.76
RPRX Royalty Pharma plc

N/A

 USD32.48B 22.60 11.90
BGNE BeiGene, Ltd

N/A

 USD31.01B N/A N/A
BNTX BioNTech SE

N/A

 USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
INCY Incyte Corporation

N/A

 USD19.83B 47.64 35.20

ETFs Containing GMAB

Symbol Name Weight Mer Price(Change) Market Cap
SCID Global X Scientific Beta .. 0.00 % 0.39 %

N/A

 USD3.34M
DX2I:F Xtrackers MSCI Europe Mid.. 0.00 % 0.25 %

+0.84 (+0.71%)

 USD0.04B
EL4C:XETRA Deka STOXX Europe Strong .. 0.00 % 0.67 %

+0.18 (+0.34%)

 USD0.25B
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.00 % 0.30 %

+0.04 (+0.35%)

 USD0.01B
DX2I:XETRA Xtrackers MSCI Europe Mid.. 0.00 % 0.25 %

+0.42 (+0.35%)

 USD0.05B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.40 %

+0.03 (+0.29%)

 USD1.87B
EL4E:F Deka STOXX Europe Strong .. 0.00 % 0.65 %

+0.17 (+0.50%)

 USD0.02B
EL4C:F Deka STOXX Europe Strong .. 0.00 % 0.67 %

+0.25 (+0.48%)

 USD0.17B
EL43:F Deka MSCI Europe MC UCITS.. 0.00 % 0.30 %

+0.04 (+0.37%)

 USD8.64M
XEUM:LSE Xtrackers MSCI Europe Mid.. 0.00 % 0.25 %

+47.00 (+0.44%)

 USD0.05B
ZXM:CA CI First Asset Morningsta.. 0.00 % 0.60 %

-0.14 (-0.38%)

 USD0.28B
EUMD:LSE iShares MSCI Europe Mid C.. 0.00 % 0.15 %

+0.03 (+0.56%)

 USD0.04B
EMID:LSE iShares MSCI Europe Mid C.. 0.00 % 0.15 %

+0.03 (+0.55%)

 USD0.04B
ZXM-B:CA CI First Asset Morningsta.. 0.00 % 0.60 %

N/A

 N/A
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

N/A

 USD0.24B
FPXE First Trust IPOX Europe E.. 0.00 % 0.70 %

N/A

 USD2.90M
FINT:CA First Trust International.. 0.00 % 0.70 %

N/A

 USD6.02M
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.40 %

+0.08 (+0.22%)

 USD0.02B
EL4E:XETRA Deka STOXX Europe Strong .. 0.00 % 0.65 %

+0.19 (+0.56%)

 USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.20% 50% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.20% 50% F 65% D
Trailing 12 Months  
Capital Gain 95.16% 75% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.16% 75% C 85% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.46% 66% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.46% 66% D 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 37.87% 69% D+ 36% F
Risk Adjusted Return 69.87% 92% A- 84% B
Market Capitalization 28.77B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.59 29% F 39% F
Price/Book Ratio 8.80 27% F 19% F
Price / Cash Flow Ratio 21.69 5% F 19% F
EV/EBITDA 3.08 40% F 88% B+
Management Effectiveness  
Return on Equity 36.46% 99% A+ 97% A+
Return on Invested Capital 17.63% 92% A- 90% A-
Return on Assets 27.27% 100% A+ 100% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.15 59% F 57% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.59 87% B+ 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.